Yemaachi Biotech, a leading genomics research company based in Ghana, has partnered with Roche to launch The African Cancer Atlas (TACA), an initiative to address the significant underrepresentation of African genomic data in global cancer research. This collaboration seeks to establish the world’s most comprehensive cancer genomic database focused on African populations, providing critical insights to drive more effective and inclusive cancer treatments.
Addressing the data gap in African cancer research.
African genomic data accounts for less than 2% of global datasets, despite Africans comprising 17% of the world’s population and possessing the most genetically diverse genomes. This lack of representation has led to gaps in understanding cancer biology and disparities in treatment outcomes for African patients. TACA will generate genomic and clinical data from up to 7,500 African cancer patients, sequencing up to 15,000 genomes (tumour and paired normal). The data collected will uncover novel cancer biomarkers and therapeutic targets, ultimately advancing precision oncology for African patients and beyond.
How will TACA work?
To deliver this ambitious project, Yemaachi will establish a consortium of pharmaceutical partners, with Roche as the anchor partner. Through its African Genomics Program, Roche will provide funding, technical input, and support to accelerate the initiative. By leveraging Roche’s expertise and resources, TACA aims to create a sustainable and equitable research model that integrates African genomic diversity into global cancer research.
Lisa Slater, Head of Roche’s African Genomics Program, also emphasized Roche’s commitment: “By partnering with Yemaachi as the consortium’s first member, we hope to leverage Africa’s genomic diversity to facilitate and accelerate healthcare solutions for cancer patients in Africa and beyond.”
Strengthening global and African research collaboration
Yemaachi’s extensive network of academic institutions and research partners—including the University of Ghana, the University of Cape Town, Dana Farber Cancer Institute, Weill Cornell Medicine, Morehouse School of Medicine, and the Francis Crick Institute—will facilitate cross-continental collaboration. Notably, African-based researchers will receive free access to TACA’s database, ensuring local scientists play a key role in driving groundbreaking cancer research on the continent.
